System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Publications

Journal Article Review Research Support, Non-U.S. Gov't Ppublish 3 citations

PubMed: 39668206 DOI: 10.1038/s41573-024-01098-w

Targeting metabolic dysfunction of CD8 T cells and natural killer cells in cancer.

Nat Rev Drug Discov 24(3):190-208

Authors: Sébastien Viel, Eric Vivier, Thierry Walzer, Antoine Marçais

Affiliations

  • Plateforme de Biothérapie et de Production de Médicaments de Thérapie Innovante, Hôpital Edouard Herriot, Hospices Civils de Lyon, Lyon, France.
  • Innate Pharma Research Laboratories, Innate Pharma, Marseille, France.
  • Aix Marseille University, CNRS, INSERM, CIML, Marseille, France.
  • APHM, Hôpital de la Timone, Marseille, France.
  • Paris Saclay Cancer Cluster, Villejuif, France.
  • Université Paris-Saclay, Gustave Roussy, Inserm, Prédicteurs moléculaires et nouvelles cibles en oncologie, Villejuif, France.
  • CIRI, Centre International de Recherche en Infectiologie, (Team Lyacts), Univ Lyon, Inserm, U1111, Université Claude Bernard Lyon 1, CNRS UMR5308 ENS de Lyon, Lyon, France.
  • CIRI, Centre International de Recherche en Infectiologie, (Team Lyacts), Univ Lyon, Inserm, U1111, Université Claude Bernard Lyon 1, CNRS UMR5308 ENS de Lyon, Lyon, France.

Abstract

The importance of metabolic pathways in regulating immune responses is now well established, and a mapping of the bioenergetic metabolism of different immune cell types is under way. CD8 T cells and natural killer (NK) cells contribute to cancer immunosurveillance through their cytotoxic functions and secretion of cytokines and chemokines, complementing each other in target recognition mechanisms. Several immunotherapies leverage these cell types by either stimulating their activity or redirecting their specificity against tumour cells. However, the anticancer activity of CD8 T cells and NK cells is rapidly diminished in the tumour microenvironment, closely linked to a decline in their metabolic capacities. Various strategies have been developed to restore cancer immunosurveillance, including targeting bioenergetic metabolism or genetic engineering. This Review provides an overview of metabolic dysfunction in CD8 T cells and NK cells within the tumour microenvironment, highlighting current therapies aiming to overcome these issues.

MeSH

Cells, Killer Cells, Natural, Pharmaceutical Preparations, Neoplasms, Therapeutics, Monitoring, Immunologic

Cited by